Goldman Sachs Group Inc. is considering sweetening the terms on $1.73 billion of leveraged loans tied to chemical maker Arclin Inc.’s acquisition of DuPont de Nemours Inc.’s Aramids business.
The bank is weighing a higher interest rate and a lower issue price to win over investors wary of the specialty chemicals industry’s demand swings, according to people familiar with the matter. Also under consideration are stronger investor protections and quarterly calls between Arclin and its lenders, the people said, asking not to be named because details are private.
Goldman Weighs Sweeter Terms on Loan Tied to DuPont Unit Sale
